139 related articles for article (PubMed ID: 1531213)
21. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
22. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
[TBL] [Abstract][Full Text] [Related]
23. Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers.
Nagasawa H; Bando M; Hori H; Satoh T; Tada T; Onoyama Y; Inayama S
Int J Radiat Oncol Biol Phys; 1992; 22(3):561-4. PubMed ID: 1735696
[TBL] [Abstract][Full Text] [Related]
24. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Dundee JW; McMillan CM; Yang J; Wright PM
Br J Clin Pharmacol; 1992 Feb; 33(2):200-1. PubMed ID: 1532323
[TBL] [Abstract][Full Text] [Related]
25. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
[TBL] [Abstract][Full Text] [Related]
26. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
Stratford IJ; Walling JM; Silver AR
Br J Cancer; 1986 Mar; 53(3):339-44. PubMed ID: 3754453
[TBL] [Abstract][Full Text] [Related]
27. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
29. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
Cobb LM; Nolan J; Butler SA
Br J Cancer; 1990 Dec; 62(6):915-8. PubMed ID: 2257219
[TBL] [Abstract][Full Text] [Related]
30. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Marschner N
Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
[TBL] [Abstract][Full Text] [Related]
31. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Harousseau JL; Zittoun R; Bonneterre J; Hedouin M; Ouvry J
Bull Cancer; 2000 Jun; 87(6):491-7. PubMed ID: 10903790
[TBL] [Abstract][Full Text] [Related]
32. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of oncogenicity for bioreductive drugs.
Hei TK; Piao CQ; He ZY; Hall EJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
[TBL] [Abstract][Full Text] [Related]
34. Phase I and other dose-ranging studies of ondansetron.
Grunberg SM
Semin Oncol; 1992 Aug; 19(4 Suppl 10):16-22. PubMed ID: 1387246
[TBL] [Abstract][Full Text] [Related]
35. Comparison of three preclinical models for nausea and vomiting assessment.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
[TBL] [Abstract][Full Text] [Related]
36. Ondansetron. Therapeutic use as an antiemetic.
Milne RJ; Heel RC
Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
[TBL] [Abstract][Full Text] [Related]
37. The role of ondansetron in paediatric patients: a review of three studies.
Stevens RF
Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy.
Fukui H; Yamamoto M
Eur J Pharmacol; 1999 May; 372(3):261-7. PubMed ID: 10395021
[TBL] [Abstract][Full Text] [Related]
39. Comparative DNA damage induced by nitroimidazole-aziridine drugs: 1. Effects of methyl substitution on drug action.
Dale LD; Tocher JH; Edwards DI
Anticancer Drug Des; 1988 Dec; 3(3):169-75. PubMed ID: 3207464
[TBL] [Abstract][Full Text] [Related]
40. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
